Protective and damaging effects of the biobehavioral stress response: Cognitive, systemic and clinical aspects: ISPNE XXXIV meeting summary

Rachel Yehuda; Bruce S. McEwen

doi:10.1016/j.psyneuen.2004.01.006

Protective and damaging effects of the biobehavioral stress response: Cognitive, systemic and clinical aspects: ISPNE XXXIV meeting summary

Rachel Yehuda
, Bruce S. McEwen

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Original language	English
Pages (from-to)	1212-1222
Number of pages	11
Journal	Psychoneuroendocrinology
Volume	29
Issue number	9
DOIs	https://doi.org/10.1016/j.psyneuen.2004.01.006
State	Published - Oct 2004

Access to Document

10.1016/j.psyneuen.2004.01.006

Cite this

@article{fd50a1a36f3643578d2b3bf71f72f3ed,

title = "Protective and damaging effects of the biobehavioral stress response: Cognitive, systemic and clinical aspects: ISPNE XXXIV meeting summary",

author = "Rachel Yehuda and McEwen, \{Bruce S.\}",

note = "Funding Information: The authors acknowledge and thank Linda M. Bierer, M.D. for her thoughtful comments on this manuscript. The authors also gratefully acknowledge unrestricted educational grants to the 34th ISPNE conference provided by: Astra Zeneca, Bristol-Myers Squibb, Eli Lilly Company, GlasxoSmithKline, Janseen Pharmaceuticals, Johnson \& Johnson, Novartis Pharmaceuticals, OrthoMcNeil, Pfizer, Inc., and Solvay Pharmaceuticals, as well as a restricted educational grant from Merck. ",

year = "2004",

month = oct,

doi = "10.1016/j.psyneuen.2004.01.006",

language = "English",

volume = "29",

pages = "1212--1222",

journal = "Psychoneuroendocrinology",

issn = "0306-4530",

publisher = "Elsevier Ltd.",

number = "9",

}

TY - JOUR

T1 - Protective and damaging effects of the biobehavioral stress response

T2 - Cognitive, systemic and clinical aspects: ISPNE XXXIV meeting summary

AU - Yehuda, Rachel

AU - McEwen, Bruce S.

N1 - Funding Information: The authors acknowledge and thank Linda M. Bierer, M.D. for her thoughtful comments on this manuscript. The authors also gratefully acknowledge unrestricted educational grants to the 34th ISPNE conference provided by: Astra Zeneca, Bristol-Myers Squibb, Eli Lilly Company, GlasxoSmithKline, Janseen Pharmaceuticals, Johnson & Johnson, Novartis Pharmaceuticals, OrthoMcNeil, Pfizer, Inc., and Solvay Pharmaceuticals, as well as a restricted educational grant from Merck.

PY - 2004/10

Y1 - 2004/10

UR - https://www.scopus.com/pages/publications/3042594885

U2 - 10.1016/j.psyneuen.2004.01.006

DO - 10.1016/j.psyneuen.2004.01.006

M3 - Article

C2 - 15219646

AN - SCOPUS:3042594885

SN - 0306-4530

VL - 29

SP - 1212

EP - 1222

JO - Psychoneuroendocrinology

JF - Psychoneuroendocrinology

IS - 9

ER -